Ocriplasmin
- Generic Name
- Ocriplasmin
- Brand Names
- Jetrea
- Drug Type
- Biotech
- CAS Number
- 1048016-09-6
- Unique Ingredient Identifier
- 7V6HE3DM5A
- Background
Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
- Indication
Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
- Associated Conditions
- Symptomatic Vitreomacular Adhesion (VMA)
Phase I RVC With Ocriplasmin for CRVO
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2018-01-08
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 4
- Registration Number
- NCT02747030
- Locations
- 🇧🇪
UZ Leuven, Leuven, Vlaams Brabant, Belgium
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
- Conditions
- Posterior Vitreous DetachmentDiabetic RetinopathyDisease Progression
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 48
- Registration Number
- NCT02681809
Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
- Conditions
- Vitreomacular AdhesionVitreomacular Traction
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 62
- Registration Number
- NCT02322229
- Locations
- 🇦🇺
Contact Alcon Laboratories (Australia) for Trial Locations, New South Wales, Australia
Assessment of Patients Treated With JETREA® for Vitreomacular Traction
- Conditions
- Vitreomacular TractionVitreomacular Adhesion
- Interventions
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 628
- Registration Number
- NCT02035748
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
- Conditions
- Symptomatic Vitreomacular Adhesion
- Interventions
- Drug: Sham injection
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 251
- Registration Number
- NCT01889251
- Locations
- 🇯🇵
Contact Alcon for Trial Locations, Tokyo, Japan
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
- Conditions
- Vitreomacular Adhesion Including Macular Hole
- Interventions
- Other: Sham injection
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 220
- Registration Number
- NCT01429441
- Locations
- 🇺🇸
Texas Retina Associates, Dallas, Texas, United States
🇺🇸Retina Associates of Cleveland, Cleveland, Ohio, United States
🇺🇸Vitroretinal Consultants, Houston, Texas, United States
Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 24
- Registration Number
- NCT01287988
- Locations
- 🇧🇪
Universitaire Ziekenhuizen K.U. Leuven, Leuven, Belgium
🇺🇸Retinal Consultants of Houston, Houston, Texas, United States
Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2018-07-31
- Target Recruit Count
- 2
- Registration Number
- NCT01194674
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 38
- Registration Number
- NCT01159665
- Locations
- 🇧🇪
University Hospital Leuven, Leuven, Belgium
Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 17
- Registration Number
- NCT01055535
- Locations
- 🇧🇪
University Hospital Leuven, Leuven, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.